NovoCure (NVCR) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free NVCR Stock Alerts $21.99 -0.18 (-0.81%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | marketbeat.comJump Financial LLC Invests $1.55 Million in NovoCure Limited (NASDAQ:NVCR)Jump Financial LLC bought a new stake in NovoCure Limited (NASDAQ:NVCR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 103,624 shares of the medical equipment provider's stock, valued at approximately $1,547,000. Jump Financial LLC owned aMay 14, 2024 | investorplace.comDouble-Up Delights: 7 Stocks Poised to Soar 100% by 2025May 13, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Stock Price Up 7.6%NovoCure (NASDAQ:NVCR) Trading Up 7.6%May 3, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPSNovoCure (NASDAQ:NVCR - Get Free Report) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. NovoCure had a negative net margin of 40.65% and a negative return on equity of 51.63%. The company had revenue of $138.50 million during the quarter, compared to analysts' expectations of $131.44 million. During the same quarter in the previous year, the business posted ($0.50) EPS. The firm's revenue was up 13.3% on a year-over-year basis.May 3, 2024 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | seekingalpha.comNovoCure Limited Q1 Earnings: Core Business AcceleratingMay 3, 2024 | fool.comNovoCure (NVCR) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comUnveiling 8 Analyst Insights On NovoCureMay 2, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Stock Price Up 10.5%NovoCure (NASDAQ:NVCR) Trading Up 10.5%May 2, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Earns "Neutral" Rating from WedbushWedbush restated a "neutral" rating and issued a $21.00 price target on shares of NovoCure in a research note on Thursday.May 2, 2024 | marketbeat.comHC Wainwright Cuts NovoCure (NASDAQ:NVCR) Price Target to $22.00HC Wainwright lowered their price target on NovoCure from $24.00 to $22.00 and set a "neutral" rating for the company in a report on Thursday.May 2, 2024 | investorplace.comNVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comNovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss ReportedMay 2, 2024 | seekingalpha.comNovoCure Limited 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | businesswire.comNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonMay 2, 2024 | businesswire.comNovocure Reports First Quarter 2024 Financial ResultsApril 30, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from AnalystsNovoCure Limited (NASDAQ:NVCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on theApril 27, 2024 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Purchased by C WorldWide Group Holding A SC WorldWide Group Holding A S boosted its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 135.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 521,784 shares of the medical equipment provider's stock after acquiring an additional 300,April 25, 2024 | marketbeat.comFederated Hermes Inc. Has $9.21 Million Position in NovoCure Limited (NASDAQ:NVCR)Federated Hermes Inc. boosted its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 807.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 616,792 shares of the medical equipment provider's stock after purApril 24, 2024 | finance.yahoo.comResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 24, 2024 | businesswire.comResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 11, 2024 | markets.businessinsider.comBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial ExecutionApril 10, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Given "Overweight" Rating at Piper SandlerPiper Sandler reaffirmed an "overweight" rating and issued a $28.00 price objective (up previously from $25.00) on shares of NovoCure in a research note on Wednesday.April 10, 2024 | marketbeat.comBaillie Gifford & Co. Sells 1,974,073 Shares of NovoCure Limited (NASDAQ:NVCR)Baillie Gifford & Co. lessened its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 29.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,840,141 shares of the medical equipment provider's stock after sellingApril 9, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Trading 4.9% Higher NovoCure (NASDAQ:NVCR) Trading 4.9% HigherApril 5, 2024 | businesswire.comNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024April 3, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Gap Down Following Analyst DowngradeNovoCure (NASDAQ:NVCR) Shares Gap Down After Analyst DowngradeApril 3, 2024 | marketbeat.comWells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00Wells Fargo & Company reduced their target price on shares of NovoCure from $49.00 to $42.00 and set an "overweight" rating for the company in a report on Wednesday.April 3, 2024 | markets.businessinsider.comNovoCure (NVCR) Receives a Buy from Wells FargoApril 2, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 6.6% NovoCure (NASDAQ:NVCR) Stock Price Down 6.6%April 1, 2024 | finance.yahoo.comNovocure to Report First Quarter 2024 Financial ResultsMarch 31, 2024 | marketbeat.comQ4 2025 EPS Estimates for NovoCure Limited (NASDAQ:NVCR) Cut by AnalystNovoCure Limited (NASDAQ:NVCR - Free Report) - Analysts at Wedbush reduced their Q4 2025 earnings estimates for shares of NovoCure in a research report issued to clients and investors on Wednesday, March 27th. Wedbush analyst D. Nierengarten now expects that the medical equipment provider will poMarch 30, 2024 | fool.comWhy NovoCure Stock Soared 18.3% This WeekMarch 29, 2024 | markets.businessinsider.comNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price TargetMarch 29, 2024 | marketbeat.comBrokers Offer Predictions for NovoCure Limited's Q4 2025 Earnings (NASDAQ:NVCR)NovoCure Limited (NASDAQ:NVCR - Free Report) - Investment analysts at Wedbush decreased their Q4 2025 earnings per share estimates for NovoCure in a report issued on Wednesday, March 27th. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will earn ($0.36) per sharMarch 28, 2024 | fool.comWhy Novocure Stock Is Jumping TodayMarch 28, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Trading Up 4.8% Following Analyst UpgradeNovoCure (NASDAQ:NVCR) Shares Up 4.8% Following Analyst UpgradeMarch 27, 2024 | seekingalpha.comNovoCure: Sell The METIS-Inspired RallyMarch 27, 2024 | marketbeat.comNovoCure's (NVCR) Neutral Rating Reiterated at WedbushWedbush reaffirmed a "neutral" rating and set a $21.00 target price on shares of NovoCure in a report on Wednesday.March 27, 2024 | markets.businessinsider.comNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s StockMarch 27, 2024 | msn.comNovocure's device shown to slow cancer progression in the brain in trialMarch 27, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring NovoCure Through Analyst InsightsMarch 27, 2024 | marketwatch.comNovocure’s stock surges after positive results in brain-cancer trialMarch 27, 2024 | markets.businessinsider.comNovocure Shares Rise After Phase 3 METIS Trial Met Primary EndpointMarch 27, 2024 | msn.comNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data ShowsMarch 27, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Price Target Raised to $24.00 at HC WainwrightHC Wainwright upped their target price on NovoCure from $22.00 to $24.00 and gave the stock a "neutral" rating in a research note on Wednesday.March 27, 2024 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Gap Up to $13.07NovoCure (NASDAQ:NVCR) Shares Gap Up to $13.07March 27, 2024 | proactiveinvestors.comNovoCure device slows spread of lung cancer to brain in late-stage study; shares riseMarch 27, 2024 | marketwatch.comNovocure Shares Surge Premarket on Phase 3 TTFields StudyMarch 27, 2024 | investing.comNovocure shares jump after trial meets primary endpoint Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… NVCR Media Mentions By Week NVCR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.790.42▲Average Medical News Sentiment NVCR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼35▲NVCR Articles Average Week Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Integra LifeSciences News ICU Medical News LeMaitre Vascular News Inari Medical News Tandem Diabetes Care News Alphatec News iRhythm Technologies News MiMedx Group News AtriCure News PROCEPT BioRobotics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCR) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
